New hints towards a precision medicine strategy for IDH wild-type glioblastoma.
journal contributionposted on 10.11.2020, 17:33 by Kieron WhiteKieron White, Kate ConnorKate Connor, James ClerkinJames Clerkin, Brona MurphyBrona Murphy, Manuela Salvucci, Alice O'FarrellAlice O'Farrell, Markus RehmMarkus Rehm, Donncha O'BrienDonncha O'Brien, Jochen PrehnJochen Prehn, SP Niclou, MLM Lamfers, M Verreault, A Idbaih, R Verhaak, A Golebiewska, Annette ByrneAnnette Byrne
Glioblastoma represents the most common primary malignancy of the central nervous system in adults and remains a largely incurable disease. The elucidation of disease subtypes based on mutational profiling, gene expression and DNA methylation has so far failed to translate into improved clinical outcomes. However, new knowledge emerging from the subtyping effort in the IDH-wild-type setting may provide directions for future precision therapies. Here, we review recent learnings in the field, and further consider how tumour microenvironment differences across subtypes may reveal novel contexts of vulnerability. We discuss recent treatment approaches and ongoing trials in the IDH-wild-type glioblastoma setting, and propose an integrated discovery stratagem incorporating multi-omics, single-cell technologies and computational approaches.
European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie ‘GLIOTRAIN’ ITN initiative [grant number 766069].
Beaumont Hospital Cancer Research and Development Trust
Institut Universitaire de Cancérologie and INCA-DGOSInserm_12560 SiRIC CURAMUS funded by the French National Cancer Institute, the French Ministry of Solidarity and Health and Inserm.
Brain Tumor Ireland
Investissements d'avenir [grant number ANR-10-IAHIAU-06]
CommentsThe original article is available at https://www.annalsofoncology.org
Published CitationWhite K, Connor K, Clerkin J, Murphy BM, Salvucci M, O'Farrell AC, Rehm M, O'Brien D, Prehn JHM, Niclou SP, Lamfers MLM, Verreault M, Idbaih A, Verhaak R, Golebiewska A, Byrne AT. New hints towards a precision medicine strategy for IDH wild-type glioblastoma. Ann Oncol. 2020;S0923-7534(20)42428-7.
Publication Date9 September 2020
- Beaumont Hospital
- Physiology and Medical Physics
- Centre for Systems Medicine
- Published Version (Version of Record)